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Elevated Dietary Magnesium Prevents Connective
Tissue Mineralization in a Mouse Model of
Pseudoxanthoma Elasticum (Abcc6/)
Jennifer LaRusso1, Qiaoli Li1, Qiujie Jiang1 and Jouni Uitto1,2
Pseudoxanthoma elasticum (PXE) is an autosomal recessive multisystem disorder characterized by ectopic
connective tissue mineralization, with clinical manifestations primarily in the skin, eyes, and cardiovascular
system. There is considerable, both intra- and interfamilial, variability in the spectrum of phenotypic
presentation. Previous studies have suggested that mineral content of the diet may modify the severity of the
clinical phenotype in PXE. In this study, we utilized a targeted mutant mouse (Abcc6/) as a model system for
PXE. We examined the effects of changes in dietary phosphate and magnesium on the mineralization process
using calcification of the connective tissue capsule surrounding the vibrissae as an early phenotypic biomarker.
Mice placed on custom-designed diets either high or low in phosphate did not show changes in mineralization,
which was similar to that noted in Abcc6/ mice on control diet. However, mice placed on diet enriched in
magnesium (fivefold) showed no evidence of connective tissue mineralization in this mouse model of PXE. The
inhibitory capacity of magnesium was confirmed in a cell-based mineralization assay system in vitro.
Collectively, our observations suggest that assessment of dietary magnesium in patients with PXE may be
warranted.
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INTRODUCTION
Pseudoxanthoma elasticum (PXE; OMIM264800) is a heri-
table multisystem disorder caused by mutations in the ABCC6
gene (for review of PXE, see Li et al., 2009). The pathologic
hallmark of this disease is ectopic mineralization of
connective tissues, primarily elastic structures, in a number
of organs. Clinically, PXE manifests in three major organ
systems, the skin, the eyes, and the cardiovascular system. In
the skin, there is an accumulation of pleiomorphic elastotic
structures in the mid-dermis, which become progressively
mineralized. Clinically, these changes manifest as yellowish
papules and plaques, which tend to coalesce to form
inelastic, leathery skin. The eye manifestations consist of
angioid streaks resulting from mineralization and breaks in
the Bruch’s membrane of the retina, and the ensuing neo-
vascularization can lead to bleeding which causes primarily
central vision loss. The cardiovascular pathology is due to
mineralization of mid-layers of the arterial blood vessels,
clinically manifesting with intermittent claudication, bleed-
ing of the gastric blood vessels, and occasionally, early
myocardial infarcts.
Timely and accurate diagnosis of PXE is often complicated
by the late onset of manifestations and considerable,
both intra- and inter-familial heterogeneity (Neldner and
Struk, 2002; Li et al., 2008b). The reasons for this phenotypic
variability are currently unknown, and attempts to
establish phenotype/genotype correlations by comparing the
types of mutations in the ABCC6 gene with phenotypic
manifestations have been largely unyielding (Pfendner
et al., 2007, 2008). It has been suggested, however, that a
number of modifier genes may contribute to the clinical
presentation, explaining, at least in part, the variability in
PXE phenotype (Scho¨n et al., 2006; Hendig et al., 2007;
Vanakker et al., 2007; Zarbock et al., 2007; Li et al.,
2008a,b). In addition, early retrospective, largely anecdotal,
studies have suggested that high intake of dairy products
(rich in calcium and phosphate) during childhood or
adolescence correlates with the severity of PXE (Renie
et al., 1984; Neldner, 1988). Finally, recent preliminary
studies suggested that treatment with an oral phosphate
binder may halt, and even reverse, the progression of
cutaneous and ocular findings in patients with PXE
(Sherer et al., 2005). These studies collectively suggested
that abnormalities in calcium/phosphate metabolism may
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contribute to the mineralization process, and therefore to the
phenotypic presentation, in PXE.
We have developed a mouse model of PXE by targeted
ablation of the Abcc6 gene in both alleles (Klement et al.,
2005). These homozygous Abcc6/ ‘‘knockout’’ (KO)
animals recapitulate the histopathologic and ultrastructural
features of human PXE by manifesting with late-onset (B5
weeks) and progressive mineralization of connective tissues
in the skin, eyes, and arterial blood vessels. We have
previously used this animal model to explore the effects of
dietary modifications on the ectopic mineralization, and our
preliminary studies suggested that the mineralization process
in PXE may be exacerbated by changes in the mineral intake
(LaRusso et al., 2007). In this study, we have specifically
examined the functions of phosphate and magnesium by
feeding these mice with custom-designed diets enriched or
depleted in these minerals. Our results indicate that increase
in dietary magnesium prevents connective tissue mineraliza-
tion in this mouse model of PXE.
RESULTS AND DISCUSSION
Experimental design
In this study, we utilized Abcc6/ mice as a model system
for PXE, which recapitulates genetic, histopathologic, and
ultrastructural features of the human disease. Although these
mice demonstrate ectopic mineralization in a number of
tissues, we utilized calcification of the connective tissue
capsule surrounding the vibrissae as a reliable biomarker of
the mineralization process (Klement et al., 2005; Jiang et al.,
2007). We have previously shown that mineralization of this
capsule is one of the early signs of the overall mineralization
process and is detectable around 5 weeks of age. The
progressive, age-associated increase in the mineralization of
the vibrissae-associated capsule can be demonstrated by
histopathologic examination of sections stained by hematox-
ylin and eosin (H&E) stain (Figure 1), or by special stains for
calcium or calcium/phosphate complexes (alizarin red and
von Kossa stains). The degree of mineralization can be
quantitated by computerized morphometric analysis of the
mineralized area in H&E-stained sections or by determination
of the calcium and phosphate content in biopsies from the
muzzle skin containing the vibrissae (Jiang et al., 2007).
High magnesium content in the diet prevents connective tissue
mineralization in Abcc6/ mice
In the experiments performed here, Abcc6/ mice at 4
weeks of age, that is, before the onset of mineralization, were
placed on specific diets, either high in phosphate, high in
magnesium, low in phosphate, or low in magnesium, as
indicated in Table 1. After 8 weeks, at the age of 12 weeks,
the mice were killed, and the degree of mineralization of the
vibrissae-associated connective tissue capsule was quanti-
tated.
Examination of the vibrissae of wild-type (WT, Abcc6þ /þ )
mice on control diet did not show any signs of mineralization
at 12 weeks of age, whereas Abcc6/ mice fed the same
control diet demonstrated clear foci of mineralization
(Figure 1, compare two left panels). This difference in
mineralization was also demonstrated by quantitative assay
of calcium and phosphate contents in the tissue, as well as by
computerized morphometric analysis of the area of miner-
alization (Figure 2).
As revealed by histopathology in Figure 1, and quantitated
by calcium/phosphate determination and by computerized
morphometric analyses in Figure 2, high or low phosphate
content of the diet did not appreciably change the degree of
mineralization, as compared to Abcc6/ mice fed control
diet. In contrast, the mineralization process in KO mice fed
with high-magnesium diet (MgO) was completely abolished,
and quantitatively these values were at the same low,
Abcc6+/+ Abcc6 –/–
Low 
magnesium (E)
Low 
phosphate (D)
High 
magnesium (C)
High 
phosphate (B)
Control diet (A)Control diet
Figure 1. Mineralization of the connective tissue capsule surrounding the bulb of vibrissae of Abcc6/ mice fed either control diet or diet with mineral
modifications. The mice were placed on special diets at 4 weeks of age, and the muzzle skin was biopsied and histopathologic sections were stained with
hematoxylin–eosin at 12 weeks. For comparison, a wild-type (Abcc6þ /þ ) mouse on control diet at 12 weeks of age is included (left panel). The Abcc6/ mice
on control diet showed distinct foci of mineralization at 12 weeks of age (arrowheads), and mice on high-phosphate, low-phosphate, or low-magnesium diet
showed similar degrees of mineralization. However, in mice fed high-magnesium diet (group C), no evidence of mineralization was noted, similar to the
Abcc6þ /þ control mice. Scale bar¼0.1mm.
Table 1. Concentrations of phosphorus and
magnesium in the experimental diets1
Content of (%)
Group Diet Phosphorus Magnesium
A Control 0.43 0.22
B High phosphate 0.85 0.22
C High magnesium 0.43 1.10
D Low phosphate 0.21 0.22
E Low magnesium 0.43 0.04
1Abcc6/ mice at 4 weeks of age were placed on diets indicated; five
mice per group.
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essentially undetectable, levels as noted in WT Abcc6þ /þ
mice. Although the KO mice fed a diet low in magnesium
content showed somewhat elevated mean value of miner-
alization, as compared to the corresponding mice fed the
control diet, this increase was not statistically significant,
largely due to considerable variation in the values (Figure 2).
In vitro confirmation of the function of magnesium in the
mineralization process
We have recently adopted a cell-based in vitro system to
identify factors that can alter the mineralization process (Jiang
et al., 2007). In this assay, human aortic smooth muscle cells
are cultured in medium containing either fetal calf serum
(10%) or serum from WT (Abcc6þ /þ ) or KO (Abcc6/)
mice. After having reached B80% of confluence, 2mM
inorganic phosphate (Pi) is added to the culture medium,
eliciting a prompt mineralization of the cell layer. The
mineralization can be visualized by phase contrast light
microscopy and can be quantitated by the measurements of
the calcium deposition in the cell layer by a chemical assay
(Figure 3). Addition of Pi into the culture medium results in
B60-fold increase in calcium deposition in the cell layer
either in the presence of fetal bovine serum (FBS) or WT
mouse serum (Figure 3b). The degree of mineralization was
even higher, about 90-fold, in cultures maintained in the
presence of Abcc6/ mouse serum, consistent with the
notion that the KO mouse serum lacks a factor(s) required to
prevent soft tissue mineralization under normal calcium and
phosphate homeostatic concentrations. However, magne-
sium in concentrations varying from 0.1 to 1.0mgml1
prevented the mineralization when added to the cultures
maintained in the presence of either WT or KO mouse serum,
in a concentration-dependent manner (Figure 3). These
observations clearly suggest that the addition of magnesium
can prevent mineralization in vitro and that the inhibition
of mineralization by magnesium noted in the Abcc6/ mice
is not mediated by systemic factors, such as hormonal
regulation.
In subsequent experiments, we allowed the mineralization
process to take place in the presence of 2mM Pi and KO
mouse serum for 14 days, after which magnesium in the same
concentrations was added to the culture medium (Figure 4).
Over the subsequent 14 days of follow-up, no change in the
degree of mineralization was noted either by microscopic
examination or by assay of calcium deposition in the cell
culture layer. The latter observations suggest that the
mineralization in this in vitro system, once it has occurred,
cannot be reversed by magnesium under these experimental
conditions.
Metabolic alterations in mice fed special diets
To examine the metabolic consequences of the experimental
diets, the serum and urine concentrations of calcium,
phosphorus, and magnesium were determined at the end of
the 8-week experimental diet (Tables 2 and 3). Relatively
little variation was noted in the serum concentrations of these
components, and the only statistically significant variation
from the control range was reduction in phosphorus
concentration in mice fed low-phosphate diet (group D;
Table 2). In contrast, significant changes were noted in
calcium and phosphorus concentrations in the urine at the
end of the 8-week diet. Specifically, over fourfold increase in
calcium concentration and 480% reduction in the phos-
phorus concentration were noted in mice fed high-magne-
sium diet (group C; Table 3). In contrast, the concentration of
calcium was reduced by B85% and the phosphorus
concentration was increased by about 50% in mice fed
low-magnesium diet (group E; Table 3). As a result of these
changes the Ca/P ratio in group A (control), group C (high
magnesium), and group E (low magnesium) were significantly
different (Po0.01).
As inhibition of ectopic mineralization by magnesium
could involve changes in the parathyroid hormone (PTH)
action (Mori et al., 1992), we also measured the serum
concentrations of PTH by an ELISA in mice fed control diet
(group A) or diet high in magnesium (group C) at 12 weeks of
age. Although considerable individual variability in PTH
values was noted, the average concentrations in group A and
group C were not statistically different: 40.5±13.6 and
56.9±26.6 pgml1, respectively (mean±SE; n¼ 3–4;
P40.5).
Putative mechanisms of magnesium-elicited inhibition of the
mineralization
Magnesium, a divalent cation, is an essential nutritional
element that is crucial to a number of physiologic processes
in humans. For example, magnesium has a function in energy
metabolism, muscle contraction, nerve impulse transmission,
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Figure 2. Quantitation of connective tissue mineralization in the vibrissae.
The wild-type (WT) and knockout (KO) mice fed control or experimental diet,
as indicated in parenthesis, was accomplished either by (a) computerized
morphometric analysis (upper panel) or (b) by chemical assay for calcium and
phosphate (lower panel) in the muzzle skin biopsies. The bars represent
mean±SE, n¼ 5 in each group. The statistical significance between different
groups is indicated by an asterisk (Po0.05).
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and bone mineralization, and it is estimated to be a required
cofactor for some 300 enzymes (Baker and Worthley, 2002).
Magnesium status is important for regulation of calcium
balance through PTH-mediated reactions, and secretion of
PTH and end-organ responsiveness to this hormone are
dependent on the availability of magnesium (Mori et al.,
1992). In this study, we demonstrate that elevated dietary
magnesium prevents connective tissue mineralization in
Abcc6/ mice, a model of PXE. Specifically, although these
KO mice reliably develop soft connective tissue mineraliza-
tion noticeable as early as the fifth week of postnatal life
when fed control diet, supplementation of the food with
magnesium completely prevented the mineralization up to at
least 12 weeks of age.
The mechanisms for the inhibition of ectopic mineraliza-
tion by magnesium could be systemic interfering with the
calcium metabolism mediated through the PTH synthesis
and/or secretion. In support of this suggestion are observa-
tions that magnesium deficiency is associated with insuffi-
cient PTH action and can lead to reduced responses to
calcitropic hormones (Mori et al., 1992). In fact, dietary
magnesium reduction to 50% of the nutrient requirement has
been shown to disrupt bone and mineral metabolism in rats
(Rude et al., 2006). An alternate mechanism may involve
direct interactions between magnesium and calcium ions in
the mineralization process. Electron microscopic and X-ray
microanalysis of the mineral deposits in PXE have shown
direct correlation between the crystalline deposits and the
presence of calcium, whereas the analysis showed these
deposits being poor in magnesium (Calap et al., 1977). At the
clinical level, treatment of patients for soft tissue mineraliza-
tion with local application of magnesium sulfate in the
calcified areas, together with oral administration of magne-
sium lactate for 4–6 months, has resulted in disappearance of
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Figure 3. Demonstration that magnesium in a dose-dependent manner inhibits mineralization and calcium deposition in an in vitro culture system. Human
aortic smooth muscle cells were cultured on tissue culture flasks in a medium containing 10% FBS or serum from WT or KO mice (10%). After the cultures
reached B80% of confluence, 2mM inorganic phosphate (þPi) was added and the degree of mineralization was assessed either (a) by phase contrast light
microscopy or (b) by chemical assay of calcium deposition in the cell layer. A dramatic, about 60-fold increase in the degree of mineralization was noted in the
presence of FBS and WT serum, and an even higher, B90-fold increase, was noted in the presence of KO mouse serum upon addition of Pi (b, left panel).
Addition of magnesium in concentrations indicated either into WT or KO mouse serum-containing culture media just before mineralization prevented the
calcium deposition in a dose-dependent manner (b, right panel). Mean±SE; n¼ 3. Scale bar¼0.1mm.
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mineral deposits, together with clinical improvement (Ditmar
and Steidl, 1989; Steidl and Ditmar, 1990). These observa-
tions suggest that dietary magnesium in amounts sufficient to
increase the total amount of magnesium in the body may be
able to prevent the mineralization of soft connective tissues.
In general, mineralization develops in several contiguous
stages: amorphous calcium phosphate is first deposited at the
early stages of the process, followed by gradual transforma-
tion into less soluble crystalline, apatite-like structures. In
corroboration of our in vivo studies on PXE mice, we were
able to prevent the calcium deposition by increasing
magnesium in an in vitro assay system in a dose-dependent
manner. However, addition of magnesium to the culture
system 14 days after the mineralization had taken place was
not able to reverse the mineral deposits. This finding could be
explained by the continuous process of mineralization
toward less soluble forms of crystalline apatite.
Conclusions and clinical implications
Our studies demonstrate that increased dietary magnesium
can prevent ectopic mineralization of connective tissues in a
mouse model of PXE, a finding that was corroborated by
in vitro findings in a cell culture system. These observations
suggest that dietary magnesium might also be helpful in
patients with PXE, a notion that can be tested in carefully
controlled clinical trials. However, additional, long-term
preclinical studies utilizing the available animal models are
required to test the potential consequences of dietary
magnesium on bone metabolism and to monitor toxicity.
Finally, it is appropriate to point out that mineral metabolism
in the mice may differ from that in humans, and the clinical
efficacy and potential side effects in humans remain to be
seen in clinical trials.
In this context, it should be noted that control of
mineralization by dietary magnesium may have broader
implications beyond PXE in situations such as arteriosclerosis.
It is of interest that a study by investigators at the Centers for
Disease Control and Prevention (CDC) in the United States,
based on a National Health and Nutrition Examination
Survey 1999–2000, concluded that substantial numbers of
US adults failed to consume adequate amounts of magnesium
in their diets (Ford and Mokdad, 2003). Collectively, these
observations suggest that careful assessment of dietary
magnesium, not only in patients with PXE but in populations
at large as well, is warranted.
MATERIALS AND METHODS
Mice and the special diets
The PXE mouse model was developed by targeted ablation of the
Abcc6 gene, as described previously (Klement et al., 2005).
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Figure 4. Cell-based mineralization assay. Using conditions similar to that
shown in Figure 3 demonstrates that addition of magnesium (0.1–1.0mgml1)
into the culture medium 14 days after the mineralization had taken place does
not reverse the process.(a) Phase contrast light microscopy; (b) calcium
deposition determined by a chemical assay. Mean±SE; n¼3. Scale
bar¼ 0.1mm.
Table 2. Calcium, phosphorus, and magnesium concentrations in the serum of Abcc6/ mice placed on different
diets1
Concentration (mean±SE) in group2
Parameter A B C D E
Calcium (mg 100ml1) 5.74±0.838 6.88±0.41 6.24±0.30 5.85±0.12 5.74±0.11
Phosphorus (mg 100ml1) 11.14±1.84 9.93±0.37 9.43±0.74 6.44±0.22* 7.81±0.56
Ca/P ratio 0.57±0.08 0.69±0.04 0.69±0.09 0.91±0.02+ 0.75±0.06
Magnesium (mg 100ml1) 3.45±0.09 3.51±0.19 4.30±0.54 4.00±0.28 3.26±0.09
1Abcc6/ mice at 4 weeks of age were placed on different diets, as indicated in Table 1. Serum concentrations of calcium, phosphorus, and magnesium
were determined at 12 weeks of age.
2Statistical significance in comparison to the control group (A) is indicated: *Po0.05; +Po0.01 (n=5).
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Heterozygous alleles were backcrossed for five generations into the
C57BL/6J background and interbred to generate Abcc6/ (KO) and
Abcc6þ /þ (WT) mice. The mice, housed in the Animal Facility of
the Thomas Jefferson University, had free access to water and were
maintained in a temperature- and humidity-controlled environment
under 12-hours light/dark cycles. Female Abcc6/ mice were
divided into five groups (A, B, C, D, and E) at 4 weeks of age and
placed on a special diet with or without mineral modifications in
phosphate and magnesium concentration for 8 weeks. All diets were
specially ordered from Harlan Teklad, Madison, WI, USA. Group A
was fed a control diet with the calcium, phosphorus, and magnesium
content found in a standard rodent diet (Table 1). Group B mice
received the same diet but with a twofold increase in phosphate,
whereas group C was fed the diet with a fivefold increase in
magnesium. Groups D and E were fed the diet with reduced
phosphate and magnesium contents, respectively. The percentage of
phosphate was decreased by 50% and the magnesium content
reduced by 80%. To monitor proper food intake and subsequent
weight gain, food was checked daily and mice were weighed
weekly.
The animal studies were approved by the Institutional Animal
Care and Use Committee of Thomas Jefferson University.
Cell cultures and induction of mineralization in vitro
Human aortic smooth muscle cells (Cascade Biologics, Portland,
OR) were cultured in DMEM growth medium. AtB80% confluence,
the cells were switched to calcification-inducing medium (DMEM
supplemented with 2mM Pi) or to normal DMEM in the presence of
either 10% fetal calf serum, or 10% mouse serum either from
Abcc6þ /þ or Abcc6/ animals, and continued to be cultured for up
to 2–4 weeks. The medium was changed every 2 days. The first day
of culture in calcification-inducing medium was defined as day 0.
For prevention experiments, magnesium (MgSO4; Fisher Scientific,
Fair Lawn, NJ) was added to some cultures at day 0 at the
concentration of 0.1, 0.5, or 1.0mgml1, for 2 weeks. For reversal
experiments, magnesium was added to some cultures at day 15 in
calcification-inducing medium at the concentration of 0.1, 0.5, or
1.0mgml1, respectively, for additional 2 weeks. All experiments
were performed in triplicate.
Quantification of calcium and calcium phosphate deposition
At day 14 or 28 of cell culture, the media were removed and the cell
layers were decalcified with 0.6 N HCl for 24 hours at room
temperature. The calcium content of the HCl supernatants was
determined colorimetrically by the o-cresolphthalein complexone
method (Calcium (CPC) Liquicolor; Stanbio Laboratory, Boerne, TX).
After decalcification, the cells were rinsed three times with
phosphate-buffered saline and solubilized with 0.1 N NaOH/0.1%
SDS at room temperature. The protein content was measured with
Protein Assay Kit (Bio-Rad, Hercules, CA), and the calcium content
of the cell layer was normalized to protein content.
To quantify the calcium deposition in mouse vibrissae, the
muzzle skin, which contains the vibrissae, was harvested and
decalcified with 0.15N HCl for 48 hours at room temperature. The
calcium content was measured as above and the phosphate content
was determined with Malachite Green Phosphate Assay kit
(BioAssay Systems, Hayward, CA). The values for calcium and
phosphate were normalized to tissue weight. Calcium and phos-
phorus in the serum and urine samples were quantitatively assayed
as above.
Quantification of magnesium in the serum and urine
The magnesium concentrations in the mouse serum and urine were
measured using the QuantiChrom Magnesium Assay Kit (BioAssay
Systems).
Serum parathyroid hormone assay
Mouse serum PTH concentrations were measured using Mouse
Intact PTH Elisa Kit (Immutopics Inc., San Clemente, CA).
Histopathology
For histopathological analysis of mineralization of vibrissae, muzzle
skin was fixed in 10% phosphate-buffered formalin, embedded in
paraffin, sectioned (5mm), and stained with H&E using standard
techniques.
Quantification of tissue mineralization by computerized
morphometric analysis
Computerized morphometric quantification was used to examine
H&E-stained sections of muzzle skin. The sections were
examined with a Nikon model Te2000 microscope furnished with
an Auto Quant Imaging system (Watervliet, New York, NY). The
number of vibrissae with and without perceptible mineralization was
established in all sections, and the extent of mineralization was
described as the percentage of area of mineralization per area of
vibrissae.
Table 3. Calcium, phosphorus, and magnesium concentrations in the urine of Abcc6/ mice placed on different
diets1
Concentration (mean±SE) in group2
Parameter A B C D E
Calcium (mg 100ml1) 20.11±5.07 18.12±4.33 82.30±9.72+ 30.79±7.03 3.06±0.86+
Phosphorus (mg 100ml1) 15.60±6.02 25.15±0.45 2.52±0.65* 9.43±5.00 22.66±0.94
Ca/P ratio 1.65±0.46 0.72±0.17 37.89±5.69+ 6.77±2.40 0.13±0.04+
Magnesium (mg 100ml1) 12.61±0.29 11.89±0.22 12.30±0.03 12.45±0.38 9.54±0.84+
1Abcc6/ mice at 4 weeks of age were placed on different diets, as indicated in Table 1. Urine concentrations of calcium, phosphorus, and magnesium
were determined at 12 weeks of age.
2Statistical significance in comparison to the control group (A) is indicated: *Po0.05; +Po0.01 (n=3–5).
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Statistical analysis
The statistical differences between the means in groups of mice
receiving various diets were calculated by the Student’s two-tailed
t-test. Comparisons of continuous measures across all groups were
completed using two-sided Kruskal–Wallis nonparametric tests
(Siegel and Castellan, 1988). The Kruskal–Wallis test is comparable
to one-way analysis of variance, but without the parametric
assumptions. Owing to small sample size, yet high computational
difficulty, exact tests based on Monte Carlo estimation are provided.
For each of the paired group comparisons, an exact two-sided
Wilcoxon’s test was computed. All statistical computations were
completed in StatXact v8.0.
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